Tuesday, August 4, 2015

FDA rejects Endo's citizen petition on opioid painkiller Opana ER and allows generics

In a stinging rebuke that will cause financial pain, the U.S. Food and Drug Administration late Friday rejected Malvern-based Endo Health Solutions' request that the agency deny approval to generic versions of its opioid painkiller Opana ER.

FDA rejects Endo's citizen petition on opioid painkiller Opana ER and allows generics

0 comments

In a stinging rebuke that will cause financial pain, the U.S. Food and Drug Administration late Friday rejected Malvern-based Endo Health Solutions' request that the agency deny approval to generic versions of its opioid painkiller Opana ER.

Last year, Endo took the unusual step of asking the agency in a citizens petition to withdraw approval of its own drug on safety grounds. Overdose deaths from opioid painkillers now exceed those by cocaine or heroin. Besides swallowing too many pills, abusers crush, liquefy, inject and smoke the drug to get high.

Endo sought approval of a new form of the drug that Endo said was tamper resistant and wanted generics blocked from entering the market. But the FDA dismissed Endo's suggestion that its request was made on safety grounds, viewing it as a way to deter generic competitors.

Endo issued a statement Friday evening that said it could cost the company $120 million in revenue in 2013 and it was "actively pursuing cost-reduction actions that will reduce the earnings effect of FDA’s decision."

It was unclear Friday evening if the cost reductions include layoffs.

 

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter